DRKS00031523招募中不适用
rheumatoid arthritis: observation of biologics treatment - RABBIT
Deutsches Rheuma-Forschungszentrum Berlin0 个研究点目标入组 30,000 人开始时间: 2023年12月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Confirmed diagnosis of rheumatoid arthritis
- •- At least 18 years of age at inclusion
- •- Onset of rheumatoid arthritis after 16 years of age
- •- Starting new therapy with an approved bDMARD (biologic Disease Modifying Anti-Rheumatic Drug) or tsDMARD (targeted synthetic Disease Modifying Anti-Rheumatic Drug) respectively with a new csDMARD (conventional synthetic Disease Modifying Anti-Rheumatic Drug) after at least one csDMARD failure or addition of a csDMARD to an existing basic therapy
排除标准
- •Patients with arthritis in the context of another autoimmune disease in the foreground, such as collagenosis or vasculitis
研究者
相似试验
终止
不适用
Response to biologics in rheumatoid arthritisInflammatory and Immune System - Rheumatoid arthritisrheumatoid arthritisACTRN12613000123741niversity of Otago, Christchurch200
已完成
不适用
Research into lower dosing of tofacitinib (Xeljanz®) when used in combination with cobicistat (Tybost®), a drug that reduces drug breakdowRheumatoid Arthritis, Psoriatic ArthritisNL-OMON26019Radboudumc30
已完成
不适用
Predicting response to biologics in rheumatoid arthritisRheumatoid arthritisACTRN12613000938707niversity of Otago, Christchurch100
招募中
不适用
Effects of therapeutic medication for rheumatoid arthritis on cachexia in patients with rheumatoid arthritis.rheumatoid arthritisJPRN-UMIN000017026Tokushima University100
已完成
不适用
Stratification of biologic therapies for rheumatoid arthritis by pathobiologyMusculoskeletal DiseasesRheumatoid arthritis, unspecifiedRheumatoid arthritisISRCTN10618686Queen Mary University of London187